Guardant Health's (GH) base business looks to be in "fundamentally good shape" and the company is poised for cash flow breakeven, excluding the screening segment, in Q4, Morgan Stanley said in a note emailed Thursday.
The company's biopharma segment continues to gain "healthy" traction as partnerships increase, the note added.
Starting this year, the company will report revenue in four different business lines: oncology, biopharma & data, licensing & other, and screening, Morgan Stanley said.
Looking ahead in Q1, oncology and screening revenue are anticipated to rise sequentially but it will not be sufficient to fully offset the decline in pharma, Morgan Stanley said, adding that after Q1, revenue should "ramp" throughout the year.
Morgan Stanley raised Guardant Health's price target to $52 from $42 and maintained an overweight rating on the stock.
Shares of the company were down 1.3% in recent Thursday trading.
Price: 42.13, Change: -0.53, Percent Change: -1.25
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.